Sun Pharmaceuticals is among several pharmaceutical companies and private equity investors that have reportedly expressed preliminary interest in buying the dermatology business of Bayer.The German pharmaceutical and agri-chemicals giant is working with JP Morgan Chase and the deal is expected to fetch $1.1 billion, a Bloomberg report said. Sun Pharma declined to comment on the development.

Apart from Sun, number one ranked generics giant Teva, Perrigo, Allergan and Spanish pharmaceutical company Almirall in combination with Galderma are also said to be considering a bid for the brands put on the block.